[196 Pages Report] The Cardiac Marker Market size was estimated at USD 3.81 billion in 2023 and expected to reach USD 4.16 billion in 2024, at a CAGR 9.71% to reach USD 7.29 billion by 2030.
Cardiac markers are substances or molecules measured in the blood to diagnose and monitor various cardiac conditions, particularly those related to heart muscle damage or stress. These markers are often used in clinical settings, such as hospitals and laboratories, to assist in diagnosing, prognosis, and monitoring cardiovascular diseases. They are particularly widely used in the diagnosis of conditions such as myocardial infarction and other forms of acute coronary syndrome. With an increased emphasis on accurate and early diagnosis in cases of cardiovascular diseases (CVD), the cardiac markers market's valuation has been progressively escalating. The rising incidence of cardiovascular conditions and the growing global geriatric population fuel the market demand for cardiac markers. Rising demand for point-of-care testing and the steady development in healthcare infrastructure, including well-equipped labs and trained personnel, globally aids the industry's growth. However, High prices associated with cardiovascular procedures and solutions affect market adoption. The evolution of the biomedical industry, particularly diagnostic technologies, and government healthcare initiatives and programs aiming to foster preventative care are instrumental in escalating the demand for cardiac markers and creating a significant growth opportunity for the market.
The Americas has a significant market landscape in the cardiac marker market due to a high prevalence of cardiovascular diseases, well-established healthcare facilities, and major market players. The increasing incidence of heart attacks and the strong focus on early diagnosis and treatment are driving the demand for cardiac marker tests in this region. Moreover, advancements in the biotechnology sector and higher adoption rates for novel diagnostics methodologies contribute to America's cardiac marker market growth. Europe's market growth in the cardiac marker is propelled by the rising aging population, which is more prone to chronic diseases, including coronary heart disease. The availability of cutting-edge healthcare facilities, rising healthcare expenditures, and favorable regulatory policies also support the growth of the European cardiac marker market. Moreover, several key market players and ongoing research activities in the cardiac biomarkers space further stimulate market growth. The Asia-Pacific region is projected to show a significant cardiac marker market growth rate during the forecast period attributed to the large population base, the rising incidences of lifestyle diseases, and the gradual improvement in healthcare infrastructure across emerging economies.
![Cardiac Marker Market Cardiac Marker Market](https://dmqpwgwn6vmm8.cloudfront.net/dimension/cardiac-marker-statistics.png?t=1725739391000)
Market Dynamics
The market dynamics represent an ever-changing landscape of the Cardiac Marker Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
- Market Drivers
- Increasing occurrence of cardiovascular diseases
- Accessibility to a large variety of reagents and kits for cardiac biomarkers
- Improved healthcare infrastructure and spending across economies
- Market Restraints
- High prices associated with cardiovascular procedures and solutions
- Market Opportunities
- Ongoing advancements in cardiac markers
- Persistent improvement in the essence of point-of-care diagnostic solution
- Market Challenges
- Stringent regulations and approvals for cardiac markers
Market Segmentation Analysis
Product: Reagents and kits provide qualitative and quantitative assessment of cardiac-specific proteins
Chemiluminescence immunoassay (CLIA) systems are sophisticated diagnostic instruments that detect high-sensitivity cardiac markers such as troponin, CK-MB, and myoglobin. These instruments utilize luminogenic substrates that emit light upon reaction with specific enzymes in the presence of the targeted antigen. Enzyme-linked immunosorbent assay (ELISA) kits and instruments are vital in detecting and quantifying cardiac markers. These assays rely on an enzyme-conjugate reaction that produces a measurable colorimetric change. ELISA systems offer flexibility in terms of scalability and are known for their specificity and high sensitivity. Immunochromatography is a rapid and simple diagnostic technique that utilizes the movement of particles along a membrane via capillary action. It involves using antibodies and antigens to detect specific biomarkers, such as cardiac markers. Immunofluorescence is a technique that uses fluorescent dyes or markers to detect the presence of specific antibodies or antigens, and it is employed for more detailed and specific analysis in the context of cardiac markers. Reagents and kits for cardiac marker detection comprise a wide range of immunoassays optimized for various analytical platforms. These consumables often include antibodies, antigens, buffers, and substrates specifically engineered for the qualitative and quantitative assessment of cardiac-specific proteins.
Biomarker Type: High adoption of BNP and NT-proBNP biomarkers for diagnosing and managing heart failure
BNP and NT-proBNP are biomarkers for diagnosing and managing heart failure. BNP is discharged by ventricular myocytes in reaction to increased wall tension, typically due to fluid overload in heart failure. When found at low levels, these peptides have a strong negative predictive value for cardiac risk and heart failure. In contrast, elevated levels are indicative of an increased risk of adverse cardiovascular events. Creatine Kinase-MB (CK-MB) is an isoenzyme of creatine kinase (CK) and is one of the traditional biomarkers for diagnosing myocardial infarction (MI). It is found mainly in cardiac cells and increases in the blood following the death of heart muscle cells. High-sensitivity C-Reactive Protein (Hs-CRP) is an acute-phase protein and a non-specific inflammatory biomarker that can indicate systemic inflammation. It is often used to assess the risk of cardiac disease and other cardiac risk factors. Myoglobin is an early but non-specific marker of myocardial injury. It is most valuable when used alongside more specific cardiac markers, such as troponins, for the early assessment of myocardial infarction. Troponin I and T are regulatory proteins that are part of the cardiac muscle contractile apparatus and are highly specific and sensitive biomarkers for myocardial injury.
Porter’s Five Forces Analysis
The porter's five forces analysis offers a simple and powerful tool for understanding, identifying, and analyzing the position, situation, and power of the businesses in the Cardiac Marker Market. This model is helpful for companies to understand the strength of their current competitive position and the position they are considering repositioning into. With a clear understanding of where power lies, businesses can take advantage of a situation of strength, improve weaknesses, and avoid taking wrong steps. The tool identifies whether new products, services, or companies have the potential to be profitable. In addition, it can be very informative when used to understand the balance of power in exceptional use cases.
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Cardiac Marker Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Cardiac Marker Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Recent Developments
Mindray Expands Cardiac Biomarker Portfolio with Launch of New Assays
Mindray has expanded its cardiac biomarker portfolio with the introduction of new assays. These assays include troponin T, high-sensitive troponin I (hsTnI), and N-terminal pro-B type natriuretic peptide (NT-proBNP). These markers are crucial for the early diagnosis and risk stratification of various cardiovascular diseases, such as acute coronary syndrome, heart failure, sepsis, and stroke. [Published On: October 23, 2023]
AUDIT MicroControls, Inc. Announces Linearity FLQ Cardiac Markers for Roche Systems
AUDIT MicroControls, Inc. partnerwed with Roche Systems of Cardiac Markers to exhibit linearity across the entire measurement range, ensuring accurate and reliable results. These systems demonstrate robust performance even in samples with complex and heterogeneous compositions. [Published On: June 29, 2023]
Cipla Launches Diagnostic Device For Multiple Health Conditions
Cipla has introduced a diagnostic device that detects various health conditions, including cardiac markers such as Troponin I and Myoglobin. This point-of-care testing device delivers reliable results quickly, making it invaluable for doctors and healthcare professionals to identify a wide range of diseases, from cardiac to infectious. [Published On: January 18, 2023]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Cardiac Marker Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Cardiac Marker Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Aehealth Limited, Becton, Dickinson and Company, BG Medicine Inc., Bio-Rad Laboratories, Inc., Biomérieux SA, Danaher Corporation, DiaSorin S.P.A., HyTest Ltd., LSI Medience Corporation, PerkinElmer Inc., QuidelOrtho Corporation, Randox Laboratories Ltd., Roche Diagnostics Ltd., Siemens Healthineers AG, Thermo Fisher Scientific Inc., and Trinity Biotech PLC.
Market Segmentation & Coverage
This research report categorizes the Cardiac Marker Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Product
- Instruments
- Chemiluminescence
- ELISA
- Immunochromatography
- Immunofluorescence
- Reagents & Kits
- Instruments
- Biomarker Type
- BNP Or NT-ProBNP
- CK-MB
- Hs-CRP
- Myoglobin
- Troponin I & T
- End-User
- Laboratory Testing Facilities
- Point of Care Testing Facilities
- Indication
- Congestive Heart Failure
- Myocardial Infarction
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
This research report offers invaluable insights into various crucial aspects of the Cardiac Marker Market:
- Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
- Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
- Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
- Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
- Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.
Additionally, the report addresses key questions to assist stakeholders in making informed decisions:
- What is the current market size and projected growth?
- Which products, segments, applications, and regions offer promising investment opportunities?
- What are the prevailing technology trends and regulatory frameworks?
- What is the market share and positioning of the leading vendors?
- What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?
- Preface
- Research Methodology
- Executive Summary
- Market Overview
- Market Insights
- Cardiac Marker Market, by Product
- Cardiac Marker Market, by Biomarker Type
- Cardiac Marker Market, by End-User
- Cardiac Marker Market, by Indication
- Americas Cardiac Marker Market
- Asia-Pacific Cardiac Marker Market
- Europe, Middle East & Africa Cardiac Marker Market
- Competitive Landscape
- List of Figures [Total: 23]
- List of Tables [Total: 467]
- List of Companies Mentioned [Total: 17]
- How big is the Cardiac Marker Market?
- What is the Cardiac Marker Market growth?
- When do I get the report?
- In what format does this report get delivered to me?
- How long has 360iResearch been around?
- What if I have a question about your reports?
- Can I share this report with my team?
- Can I use your research in my presentation?